Hsu Jason's Form 4 filing
Immix Biopharma, Inc. (IMMX) · filed Sep 18, 2023
- Accession no.
- 0001493152-23-032969
- Filed
- Sep 18, 2023
- Trade date
- Sep 11-15, 2023
- Filing delay
- 7 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market purchases total $200.4K. It was filed 7 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Hsu JasonCIK 0001895035 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 11, 2023 | Common Stock | PPurchaseAcquired | +25,000 | $2.89 | +$72,250 | 710,000 | Direct | |
| Sep 12, 2023 | Common Stock | PPurchaseAcquired | +30,000 | $2.83 | +$84,900 | 740,000 | Direct | |
| Sep 14, 2023 | Common Stock | PPurchaseAcquired | +10,000 | $2.58 | +$25,800 | 750,000 | Direct | |
| Sep 15, 2023 | Common Stock | PPurchaseAcquired | +7,000 | $2.49 | +$17,430 | 757,000 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.